Dr Hugh McMillan is an Associate Professor in the Division of Pediatric Neurology at McGill University. His area of clinical expertise is caring for children and youth with inherited and acquired disorders of peripheral nerve, muscle and neuromuscular junction. He follows children in the Neuro-Oncology clinic as well as a General Child Neurology clinic. His research interests include clinical research, clinical trials (investigator-initiated and sponsor-initiated studies) as well as translational research in cooperation with basic scientists. He has been an author or co-author of more than 55 publications in peer-reviewed journals. He recently co-edited a textbook, “Pediatric Electromyography: Concepts and Clinical Applications”. He is active in the community as a Member of the Muscular Dystrophy Canada Scientific Advisory Board and is the Chair of the Canadian Pediatric Neuromuscular Group.
Katz, SL, Blinder, H, Newhook, D, Bmus, LA, Nicholls, S, McMillan, HJ et al.. Understanding the experiences of lung volume recruitment among boys with Duchenne muscular dystrophy: A multicenter qualitative study. Pediatr Pulmonol. 2022. PMID:36102618
Guglieri, M, Clemens, PR, Perlman, SJ, Smith, EC, Horrocks, I, Finkel, RS et al.. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID:36036925
Mirchi, A, Richer, J, Oskoui, M, McMillan, HJ. NTRK1-related Hereditary Sensory and Autonomic Neuropathy Type 4: The Role of the Histamine Challenge Test. Child Neurol Open. .9 2329048X221108826 PMID:35756968
Strauss, KA, Farrar, MA, Muntoni, F, Saito, K, Mendell, JR, Servais, L et al.. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022.28 (7)1390-1397 PMID:35715567
Strauss, KA, Farrar, MA, Muntoni, F, Saito, K, Mendell, JR, Servais, L et al.. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022.28 (7)1381-1389 PMID:35715566See more on PubMed